Factsheet Lithuania



Lifescience landscape



Life Science HUB - 80 + biotech and life science companies

Economic impact - sector contributes 2.5% of GDP

Global reach - exports to 100+ countries wordwide



Healthcare support - Drives innovation, partnerships, and advanced therapies

BioCity - a hub of alive technologies



- Led by: Northway Group (subsidiaries: Northway Biotech, Celltechna)
- First facility: Gene Therapy Centre under construction, completion in 2024
- Expansion by 2030: R&D & Virology Centre, Life Science Industry Hub Smart Service Centre, Large-Scale Microbial Production Centre, Large-Scale Mammalian Production Centre, and Stem Cell & 3D Bioprinting Centre
- Scale: campus area equals 10 football fields
- Investment: €7 billion over the next decade

Funding



- Scale: One of Europe's largest biotech investments (~€7 billion over 10 years)
- First facility: Gene Therapy Centre (€50 million), opening in 2024
- Jobs: 100+ new positions in the first phase; ~2,100 specialists once fully operational

Digital Health Infrastructure



- Infrastructure six complexes with GMP manufacturing plants and research centers (virology, stem cells, 3D bioprinting)
- Integration combines R&D, production, and smart services in one ecosystem
 Impact accelerates innovation, boosts interoperability, and attracts global
- biotech partnerships

Vision



"BIO CITY will be a frontrunner in European biotech by uniting diverse fields into one ecosystem, catalysing collaboration and rapid innovation."

– Prof. V. A. Bumelis

Challenges & Priorities



Issues:

- Need to strengthen Lithuania's position in global life sciences
 I imited international visibility and partnerships
- Limited international visibility and partnerships
- Pressure to increase competitiveness in high-tech healthcare sectors

National priorities:

- Strengthen leadership in life sciences
- Expand international partnerships
- Boost R&D intensity, exports, and job creation through biotech and digital health innovation



